Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6423
    -0.0003 (-0.04%)
     

  • OIL

    82.96
    +0.23 (+0.28%)
     

  • GOLD

    2,407.60
    +9.60 (+0.40%)
     

  • Bitcoin AUD

    100,358.05
    +1,436.74 (+1.45%)
     

  • CMC Crypto 200

    1,386.88
    +74.25 (+6.00%)
     

  • AUD/EUR

    0.6027
    -0.0004 (-0.07%)
     

  • AUD/NZD

    1.0896
    +0.0021 (+0.19%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,158.25
    -236.06 (-1.36%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,942.17
    +166.79 (+0.44%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update

Xenon Pharmaceuticals Inc.
·1-min read
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, May 10, 2022.

Conference Call/Webcast Information:

Date:

Tuesday, May 10, 2022

Time:

4:30 pm Eastern Time (1:30 pm Pacific Time)

Dial-In Number:

855-779-9075

International Dial-In:

631-485-4866

Conference ID:

2263884

The webcast will also be broadcast live on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.

ADVERTISEMENT

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com